Miller Howard Investments Decreased Nisource Com (NI) Position By $323,173; 5 Bullish Analysts Covering Global Blood Therapeutics, Inc. (GBT)

June 19, 2018 - By Ellis Scott

NiSource Inc. (NYSE:NI) Logo

Among 5 analysts covering Global Blood Therapeutics (NASDAQ:GBT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Global Blood Therapeutics had 8 analyst reports since September 8, 2015 according to SRatingsIntel. The firm has “Overweight” rating given on Tuesday, September 8 by Morgan Stanley. The company was initiated on Tuesday, September 8 by Goldman Sachs. The stock has “Outperform” rating by Wedbush on Tuesday, October 25. The rating was maintained by Empire with “Buy” on Friday, June 17. The firm has “Outperform” rating by Wedbush given on Tuesday, September 8. The rating was initiated by Cowen & Co on Tuesday, September 8 with “Outperform”. JP Morgan initiated Global Blood Therapeutics, Inc. (NASDAQ:GBT) on Wednesday, January 4 with “Overweight” rating. See Global Blood Therapeutics, Inc. (NASDAQ:GBT) latest ratings:

Miller Howard Investments Inc decreased Nisource Inc Com (NI) stake by 16.14% reported in 2018Q1 SEC filing. Miller Howard Investments Inc sold 14,051 shares as Nisource Inc Com (NI)’s stock rose 6.40%. The Miller Howard Investments Inc holds 73,017 shares with $1.75 million value, down from 87,068 last quarter. Nisource Inc Com now has $8.85 billion valuation. The stock increased 0.54% or $0.13 during the last trading session, reaching $24.39. About 2.10M shares traded. NiSource Inc. (NYSE:NI) has declined 1.68% since June 19, 2017 and is downtrending. It has underperformed by 14.25% the S&P500. Some Historical NI News: ; 14/03/2018 – Glancy Prongay & Murray LLP Commences Investigation on Behalf of NiSource Inc. Investors (Nl); 11/05/2018 – NiSource: Selling Stockholders Include T. Rowe Price, Capital Research and Management, ZP Master Utility Fund, Citadel; 23/04/2018 – NiSource: Agreement Reached in NIPSCO’s Proposal to Modify Natural Gas Rates; 13/04/2018 – Columbia Gas of Maryland Files to Recover Investment in Replacing Aging Infrastructure; 02/05/2018 – NiSource: On Track for $1.7B-$1.8B Utility Infrastructure Investments in 2018; 16/03/2018 – DEEP ECO: NiSource May Benefit, Industry Posts 5th Straight Gain; 19/04/2018 – NISOURCE – UNDER AGREEMENT, CO BORROWED INITIAL TRANCHE OF $150 MLN ON APRIL 18, MAY BORROW SECOND TRANCHE OF UP TO $450 MLN PRIOR TO JUNE 15, 2018; 02/05/2018 – NiSource 1Q Adj EPS 77c; 02/05/2018 – NISOURCE SAYS L-T GUIDANCE, GROWTH, CAPEX VIEWS REAFFIRMED; 08/05/2018 – NiSource Declares Dividend of 19.5c

Analysts await NiSource Inc. (NYSE:NI) to report earnings on August, 1. They expect $0.11 EPS, up 10.00% or $0.01 from last year’s $0.1 per share. NI’s profit will be $39.90 million for 55.43 P/E if the $0.11 EPS becomes a reality. After $0.77 actual EPS reported by NiSource Inc. for the previous quarter, Wall Street now forecasts -85.71% negative EPS growth.

Miller Howard Investments Inc increased Aegon N V Ny Registry Sh (NYSE:AEG) stake by 8.86 million shares to 9.53M valued at $64.53M in 2018Q1. It also upped Sempra Energy Com (NYSE:SRE) stake by 8,364 shares and now owns 61,429 shares. Fortis Inc Com (FRTSF) was raised too.

Since May 7, 2018, it had 2 buys, and 2 insider sales for $103,200 activity. Another trade for 14,500 shares valued at $362,790 was made by Vegas Pablo on Friday, May 25. Disser Peter T sold $166,078 worth of stock or 6,732 shares. The insider Smith Teresa M sold 15,748 shares worth $399,212. $99,300 worth of NiSource Inc. (NYSE:NI) was bought by BUTLER ERIC L on Wednesday, May 9.

Among 16 analysts covering Nisource Inc. (NYSE:NI), 9 have Buy rating, 0 Sell and 7 Hold. Therefore 56% are positive. Nisource Inc. had 39 analyst reports since August 20, 2015 according to SRatingsIntel. The rating was downgraded by Credit Suisse on Friday, August 19 to “Underperform”. The company was maintained on Wednesday, December 20 by Jefferies. Credit Suisse maintained NiSource Inc. (NYSE:NI) rating on Thursday, November 2. Credit Suisse has “Outperform” rating and $30 target. The rating was upgraded by JP Morgan to “Overweight” on Thursday, May 17. The stock of NiSource Inc. (NYSE:NI) has “Buy” rating given on Thursday, May 17 by J.P. Morgan. The firm earned “Buy” rating on Monday, November 20 by Citigroup. The company was maintained on Monday, May 7 by Credit Suisse. The stock of NiSource Inc. (NYSE:NI) earned “Buy” rating by KeyBanc Capital Markets on Wednesday, October 18. The stock has “Hold” rating by Jefferies on Monday, October 16. The firm has “Neutral” rating by JP Morgan given on Tuesday, March 29.

Investors sentiment decreased to 0.9 in 2018 Q1. Its down 0.56, from 1.46 in 2017Q4. It is negative, as 37 investors sold NI shares while 137 reduced holdings. 38 funds opened positions while 118 raised stakes. 293.09 million shares or 4.30% more from 281.01 million shares in 2017Q4 were reported. Miller Howard Invests Inc New York accumulated 73,017 shares. Moreover, Teacher Retirement Sys Of Texas has 0.01% invested in NiSource Inc. (NYSE:NI). Parkside Fincl Bank And Trust has 0% invested in NiSource Inc. (NYSE:NI). Lmr Partners Llp holds 0.06% or 21,999 shares. State Treasurer State Of Michigan stated it has 0.02% in NiSource Inc. (NYSE:NI). Energ Income Partners Limited Liability invested in 0.46% or 991,269 shares. Keybank Association Oh has 0.03% invested in NiSource Inc. (NYSE:NI) for 191,074 shares. 29,498 are owned by Dekabank Deutsche Girozentrale. America First Advisors Ltd Liability, a Nebraska-based fund reported 2,000 shares. Moreover, Rbo And Limited Liability Corp has 1.84% invested in NiSource Inc. (NYSE:NI) for 302,973 shares. 513,859 were reported by Principal Fincl Group. Comm State Bank owns 10,714 shares or 0% of their US portfolio. Utah Retirement holds 62,684 shares or 0.03% of its portfolio. 12,580 were reported by Lynch & Associate In. Hbk Limited Partnership invested 0.02% in NiSource Inc. (NYSE:NI).

Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood disorders. The company has market cap of $2.16 billion. The Company’s lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. It currently has negative earnings. The firm is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities.

More notable recent Global Blood Therapeutics, Inc. (NASDAQ:GBT) news were published by: Nasdaq.com which released: “GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European …” on June 15, 2018, also Nasdaq.com with their article: “GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease (SCD) Program at …” published on June 08, 2018, Seekingalpha.com published: “GBT’s voxelotor shows lower treatment effect in adolescents with SCD in mid-stage study; shares slip 4% premarket” on June 15, 2018. More interesting news about Global Blood Therapeutics, Inc. (NASDAQ:GBT) were released by: Streetinsider.com and their article: “Pre-Open Stock Movers 06/15: (VSTM) (TXMD) (GLUU) Higher; (AFMD) (GBT) (GNK) Lower (more…)” published on June 15, 2018 as well as Nasdaq.com‘s news article titled: “Mid-Day Market Update: Dow Down Over 200 Points; Affimed Shares Plummet” with publication date: June 15, 2018.

The stock increased 4.24% or $1.7 during the last trading session, reaching $41.75. About 1.88M shares traded or 143.35% up from the average. Global Blood Therapeutics, Inc. (NASDAQ:GBT) has risen 60.31% since June 19, 2017 and is uptrending. It has outperformed by 47.74% the S&P500. Some Historical GBT News: ; 16/03/2018 – Global Blood Collection Market – Increasing Cases of Cancer to Boost Growth | Technavio; 03/04/2018 – GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference; 09/05/2018 – Rounds Report: Global Blood Therapeutics Rallied While Improving FDA Policies To Help Nektar; 22/04/2018 – DJ Global Blood Therapeutics Inc, Inst Holders, 1Q 2018 (GBT); 10/05/2018 – Global Blood Plasma Derivatives Market Expected to Reach $44,333 Million by 2023 – Allied Market Research; 25/04/2018 – Hartford Healthcare Adds Global Blood, Exits NanoString; 09/05/2018 – Global Blood at American Thoracic Society Meeting May 18; 04/04/2018 – Global Blood Presenting at Conference Apr 10; 26/03/2018 – Global Blood Presenting at Conference Tomorrow; 26/05/2018 – Global Blood Pressure Monitoring Testing Market – Rising Preference for Home Healthcare to Boost Growth l Technavio

NiSource Inc. (NYSE:NI) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>